The Botulinum Toxin Innovation: From Powder to Liquid.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
29
8
2024
pubmed:
29
8
2024
entrez:
28
8
2024
Statut:
ppublish
Résumé
Botulinum toxin (BoNT) has evolved as a popular treatment for various medical and aesthetic conditions since the 1980s. The emergence of new liquid formulation BoNT products in the industry highlights the need to evaluate the value and advantages of these modern formulations. The aim of this review was to assess and compare the expected difference in practice between liquid and powder formulation BoNT products. This article involves a review of pertinent guidelines, product information from manufacturers, available database for safety reports, and survey results. Guidelines and safety reports have pointed out potential risks in the reconstitution process, while medication preparation steps are simplified in liquid formulation. The shift toward ready-to-use liquid products can mitigate risks related with reconstitution errors and potentially enhancing patient care by saving time and cost associated with medication preparation.
Sections du résumé
BACKGROUND
BACKGROUND
Botulinum toxin (BoNT) has evolved as a popular treatment for various medical and aesthetic conditions since the 1980s. The emergence of new liquid formulation BoNT products in the industry highlights the need to evaluate the value and advantages of these modern formulations.
OBJECTIVE
OBJECTIVE
The aim of this review was to assess and compare the expected difference in practice between liquid and powder formulation BoNT products.
PAITENTS AND METHODS/MATERIALS
UNASSIGNED
This article involves a review of pertinent guidelines, product information from manufacturers, available database for safety reports, and survey results.
RESULTS
RESULTS
Guidelines and safety reports have pointed out potential risks in the reconstitution process, while medication preparation steps are simplified in liquid formulation.
CONCLUSION
CONCLUSIONS
The shift toward ready-to-use liquid products can mitigate risks related with reconstitution errors and potentially enhancing patient care by saving time and cost associated with medication preparation.
Identifiants
pubmed: 39196833
doi: 10.1097/DSS.0000000000004358
pii: 00042728-202409001-00011
doi:
Substances chimiques
Powders
0
Botulinum Toxins, Type A
EC 3.4.24.69
Neuromuscular Agents
0
Botulinum Toxins
EC 3.4.24.69
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S48-S51Informations de copyright
Copyright © 2024 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Pickett A, Perrow K. Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol 2010;9:1085–91.
Ting PT, Anatoli F. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med 2004;4:258–61.
Aesthetic Plastic Surgery National databank Statistics. The Aesthetic Society Web Site; 2022. Available from: http://www.surgery.org. Accessed February 8, 2024.
Izutsu Kl. Application of freezing and freeze-drying in pharmaceutical formulation. Adv Exp Med Biol 2018;1081:371–83.
European Medicines Agency. Good Practice Guide on Risk minimization and Prevention of Medication Errors; 2014. Available from: http://www.ema.europa.eu/system/files/documents/regulatory-procedural-guideline/WC500196981_en_pdf. Accessed June 15, 2024.
FDA. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed Feburary 29, 2024.
Bart EKSS, Golsteijn SC, van Rootselaar A, Koelman JH. A cautionary Note: botulinum toxin for cervical dystonia reconstituted in sterile water: more pain, still gain. Mov Disord Clin Pract 2021;9:125–6.
Wayne DC. Incorrect reconstitution of incobotulinum toxin leads to less neurotoxin. J Drug Dermatol 2014;13:735–8.
U.S. Centers for Disease Control and Prevention. Reconstitute Lyophilized Vaccine. Available from: https://www.youtube.com/watch?v=oZAOqlk3TBA
Botox. Full Prescribing Information. Available from: https://www.rxabbvie/pdf/botox_pi_pdf. Accessed June 15, 2024.
Dysport. Full Prescribing Information. Available from: https://www.dysportusa.com/hcp. Accessed June 15, 2024.
Xeomin. Full Prescribing Information. Available from: https://www.xeominaesthetic.com/wp-content/uploads/XEOMIN-Prescribing-information. Accessed June 15, 2024.
Data on File. MT10109L Investigator’ Meeting. 2023.